Oncogene profile of papillary thyroid carcinoma

Surgery

Volumn 125, Issue 1, 1999, Pages 46-52

  Sugg, Sonia L ^a,b   Ezzat, Shereen ^a   Zheng, Lei ^a   Freeman, Jeremy L ^a   Rosen, Irving B ^a   Asa, Sylvia ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MALE; METASTASIS; ONCOGENE; ONCOGENE NEU; ONCOGENE RAS; ONCOGENE RET; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; THYROID PAPILLARY CARCINOMA;

EID: 0032940645     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70287-4     Document Type: Article

References (32)

1. 1. LiVolsi VA. Surgical pathology of the thyroid. Philadelphia: WB Saunders; 1990.
2. 2. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988;12:22-27.
3. 3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
4. 4. Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocrinol Pathol 1997;8:21-8.
5. 5. Sugg SL, Zheng L, Rosen IB, et al. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 1996;81:3360-5.
6. 6. Ezzat S, Zheng L, Kolenda J, et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 1996;6:409-16.
7. 7. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma [review]. J Lab Clin Med 1994;123:331-7.
8. 8. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple ret/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998;83. In press.
9. 9. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
10. 10. Sauter G, Moch H, Moore D, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993;53:2199-203.
11. 11. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1995;77:71-8.
12. 12. Soares P, Sambade C, Sobrinho-Simoes M. Expression of c-erbB-2 in tumours and tumour-like lesions of the thyroid [letter]. Int J Cancer 1993;56:459-61.
13. 13. Haugen DRF, Akslen LA, Varhaug JE, Lillehaug JR. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 1992;65:832-7.
14. 14. Aasland R, Lillehaug JR, Male R, et al. Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. Br J Cancer 1988;57:358-63.
15. 15. Sugg SL, Ezzat S, Zheng, Rosen IB, Freeman JL, Asa SL. Cytoplasmic staining of erbB-2 but no mRNA levels correlates with differentiation in human thyroid neoplasm. Clin Endocrinol 1998. In press.
16. 16. Namba H, Rubin SA, Fagin FA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474-9.
17. 17. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4:159-64.
18. 18. Salvatore D, Celetti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumours: p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 1996;134:177-83.
19. 19. Busmanis I, Feleppa F, Jones A, et al. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology 1994;26:261-7.
20. 20. Corbett IP, Henry JA, Angus B, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990;161:15-25.
21. 21. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989.
22. 22. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43.
23. 23. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989;4:1153-7.
24. 24. Ezzat S, Zheng L, Smyth HS, Asa SL. The c-erbB-21neu proto-oncogene in human pituitary tumors. Clin Endocrinol 1997;46:599-606.
25. 25. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of ret rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1996;11:2459-67.
26. 26. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990;5:565-70.
27. 27. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990;50:8002-9.
28. 28. Dougall WC, Qian X, Peterson NC, et al. The new-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994;9:2109-23.
29. 29. Guy GT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J Biol Chem 1996;271:7673-8.
30. 30. Lemoine NR, Staddon S, Dickson C, Barnes DM, Cullick WJ. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 1990;5:237-9.
31. 31. Grieco D, Santoro M, Dathan NA, Fusco A. Activated RET oncogene products induce maturation of xenopus oocytes. Oncogene 1995;11:113-7.
32. 32. Romano A, Wong WT, Santoro M, et al. The high transforming potency of erbB-2 and ret is associated with phosphorylation of paxillin and 23 kDa protein. Oncogene 1994;9:2923-33.